SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refra...
SAN FRANCISCO--(BUSINESS WIRE)-- #manufacturing--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced the launch of its collaboration with Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in the cell therapy space. This initiative will be focused on automating cell therapy manufa...
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negot...
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET.
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timas...
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.